Can B Corp. Reorganizes Under Nascent Pharma Holdings to Focus on Cannabis Patents

Can B Corp. (OTCQB: CANB) has announced a significant reorganization, resulting in the creation of Nascent Pharma Holdings, Inc. as its new publicly-traded parent company. This strategic move is designed to streamline the company's efforts in safeguarding and monetizing cannabis patents, a shift that was initially signaled in March 2024. The reorganization entails the automatic conversion of Can B's existing shares into Nascent Pharma Holdings, Inc. shares on a one-for-one basis, with the current Board and executive officers retaining their positions within the new structure.

The transition to Nascent Pharma Holdings, Inc. underscores Can B's commitment to leveraging its cannabis-related intellectual property, including two issued patents registered with the US Patent and Trademark Office. These patents cover cannabis extracts and their methods of preparation, highlighting the company's focus on both the composition and use of cannabis products. The reorganization is anticipated to facilitate capital raising efforts, enabling the company to pursue business opportunities such as partnerships, licensing agreements, and litigation funding to protect its patents.

While the name change and the issuance of a new trading symbol are currently under review by FINRA, shares will continue to trade under the 'CANB' symbol until the process is finalized. This development is pivotal for the cannabis and psychedelic industries, as it reflects the growing importance of intellectual property in these sectors. The ability to protect and commercialize patents is crucial for companies aiming to establish a competitive edge and drive innovation in the rapidly evolving cannabis market.

For more information, visit https://nascentpharmaholdings.com.